

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, December 9, 2020
Alfresa Holdings Corporation

**Notice regarding an Accusation against a Consolidated Subsidiary etc.
Regarding a Suspected Violation of the Antimonopoly Act**

Today, our Company's consolidated subsidiary, Alfresa Corporation (head office: Chiyoda-ku, Tokyo), and its employees were named in an accusation lodged by the Japan Fair Trade Commission for allegedly violating the Antimonopoly Act when bidding to supply ethical pharmaceuticals ordered by the Japan Community Health care Organization (JCHO).

These developments are extremely regrettable. We sincerely apologize for the great inconvenience and concern that they may cause to our shareholders, customers, business partners, and all other stakeholders.

Our Company will continue to fully cooperate with the investigation by the relevant authority. In the meantime, all Group management members and employees across the board will scale up their efforts to ensure fuller compliance with all laws and regulations and strive to regain the trust of stakeholders as soon as possible.